{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-026024","form_type":"8-K","ticker":"SCNX","cik":"0001382574","company_name":"Scienture Holdings, Inc.","filed_at":"2023-07-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.749748+00:00","generated_at":"2026-06-12T21:53:12.496807+00:00","sec_items":["1.01","2.01","5.02","7.01","8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"TRxADE closes Superlatus acquisition, regains Nasdaq compliance","bullets":["Acquired Superlatus; shareholders received 136,441 common shares (19.99% stake) and 306,855 Series B Preferred (100:1 conversion).","Issued MEDS Rights: 7 rights per share held on July 28, 2023; each right allows one free common share upon signing registration rights agreement.","Appointed Candice Beaumont as director; she is Superlatus's Executive Director with 20+ years in finance, banking, M&A.","Regained compliance with Nasdaq's $2.5M minimum stockholders' equity requirement under listing rule 5550(b)(1).","Lock-up agreements: 360-day restriction on sale/transfer of shares for certain Superlatus and MEDS stockholders."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-026024","json":"https://secwatch.observer/filing/0001493152-23-026024.json","markdown":"https://secwatch.observer/filing/0001493152-23-026024.md","text":"https://secwatch.observer/filing/0001493152-23-026024.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1382574/000149315223026024/0001493152-23-026024-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1382574/000149315223026024/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T21:53:12.496807+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"803b63bfb52d601f5ac5e9548dc8ef54feee6272","claim":"Scienture Holdings, Inc. completed an acquisition involving Superlatus, Inc. for 136,441 shares of common stock of the Company, representing 19.9% of the total issued and outstanding common stock of the Company after the consummation of the (closed 2023-07-31).","evidence_excerpt":"the surviving entity in the Merger. Under the terms of the A&R Merger Agreement, at the closing of the Merger (the “Closing”), shareholders of Superlatus received in aggregate 136,441 shares of common stock of the Company, representing 19.9% of the total issued and outstanding common stock of the Company after the consummation of the Merger and 306,855 shares","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1382574/000149315223026024/0001493152-23-026024-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"acquisition"},{"label":"Counterparty","value":"Superlatus, Inc."},{"label":"Consideration","value":"136,441 shares of common stock of the Company, representing 19.9% of the total issued and outstanding common stock of the Company after the consummation of the"},{"label":"Closing","value":"2023-07-31"}],"fact_type":"ma_transaction"},{"claim_id":"61c30b183664f9090b9cd86387394a470c995c8b","claim":"Scienture Holdings, Inc. entered into Amended and Restated Agreement and Plan of Merger with Superlatus, Inc. valued at 136,441 shares of common stock ... and 306,855 shares of Company's Series B Preferred Stock (effective 2023-07-14).","evidence_excerpt":"on July 14, 2023, TRxADE HEALTH, Inc., a Delaware corporation (the \"Company\" or \"MEDS\") entered into a certain Amended and Restated Agreement and Plan of Merger (the \"A&R Merger Agreement\") with Superlatus, Inc., a U.S.-based holding company of food products and distribution capabilities (\"Superlatus\") and Foods Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of the Company (\"Merger Sub\").","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1382574/000149315223026024/0001493152-23-026024-index.htm","confidence":0.87,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"merger"},{"label":"Counterparty","value":"Superlatus, Inc."},{"label":"Value","value":"136,441 shares of common stock ... and 306,855 shares of Company's Series B Preferred Stock"},{"label":"Effective","value":"2023-07-14"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}